Dorman Products, Inc. - Common Stock (DORM)
115.00
-0.37 (-0.32%)
NASDAQ · Last Trade: Apr 6th, 10:30 PM EDT
A fundamental analysis of (NASDAQ:DORM): DORMAN PRODUCTS INC (NASDAQ:DORM) can be considered a quality stock. Here's why.
Via Chartmill · April 4, 2025

A fundamental analysis of (NASDAQ:DORM): Is DORMAN PRODUCTS INC (NASDAQ:DORM) a Strong Candidate for Quality Investing?
Via Chartmill · March 4, 2025

Via Benzinga · November 1, 2024

DORM stock results show that Dorman Prods beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024

The automotive products company missed earnings estimates for its third quarter.
Via The Motley Fool · October 31, 2023

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via Benzinga · February 27, 2024

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.
Via Benzinga · February 27, 2024

Via Benzinga · March 3, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Via Benzinga · February 26, 2024

Via Benzinga · October 24, 2022

Dorman Products (NASDAQ:DORM) reported its Q3 earnings results on Monday, October 24, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via Benzinga · October 24, 2022

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment.
Via Benzinga · October 31, 2023

Via Benzinga · October 31, 2023

U.S. stocks closed higher on Tuesday, with the Dow Jones gaining over 300 points. Here is the list of some big stocks recording losses in the previous session.
Via Benzinga · October 26, 2022

Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.
Via Benzinga · October 26, 2022

On Tuesday, 120 companies set new 52-week lows.
Via Benzinga · October 25, 2022

Analysts have provided the following ratings for Dorman Products (NASDAQ:DORM) within the last quarter:
Via Benzinga · October 25, 2022

Pulled from Benzinga Pro data, Dorman Products (NASDAQ:DORM) posted Q3 earnings of $30.60 million, an increase from Q2 of 19.27%. Sales dropped to $413.47 million, a 0.95% decrease between quarters.
Via Benzinga · October 25, 2022

Supply disruptions linger and demand clouds have gathered.
Via Investor's Business Daily · October 24, 2022